SIRDALUD

Main information

  • Trade name:
  • SIRDALUD 4 mg tablet
  • Dosage:
  • 4 mg
  • Pharmaceutical form:
  • tablet
  • Prescription type:
  • Prescription only
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • SIRDALUD 4 mg tablet
    Finland
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • Tizanidine
  • Product summary:
  • Suitability for use in older adult patients Tizanidini hydrochloridum Avoid using in older persons. Slightly anticholinergic. Slightly sedative. Risk of QT prolongation. In severe renal insufficiency, administer only once a day. Significant adverse effects include hypotension, tiredness and torsades de pointes ventricular tachycardia. Take interactions into account.

Status

  • Source:
  • Fimea
  • Authorization status:
  • Marketing authorization granted
  • Authorization number:
  • 9260
  • Authorization date:
  • 10-04-2008
  • Last update:
  • 26-07-2018